Skip Ribbon Commands
Skip to main content
Dr Teo Ching Ching Melissa from National Cancer Centre Singapore

Adj Prof Melissa Teo Ching Ching


Head & Senior Consultant

Specialty: Surgical Oncology, General Surgery

Sub-specialties: Colorectal, Gastrointestinal, Pelvic & Peritoneal, Sarcoma, Skin & Melanoma

Clinical Appointments

  • Head & Senior Consultant Division of Surgical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Senior Consultant General Surgery Singapore General HospitalSingapore General Hospital

Academic Appointments

  • Adjunct Professor


Adjunct Prof Teo is the Head of the Division of Surgical Oncology at the National Cancer Centre Singapore. She completed her surgical residency in Singapore (2007) and was awarded the Singhealth HMDP Award to pursue sub-specialty training in complex intra-abdominal and pelvic surgery in the University of Toronto/ Princess Margaret Hospital, Toronto, Canada. Upon completion of an SSO-accredited Surgical Oncology Fellowship, she pursued and completed a second Fellowship in Colorectal Surgery.

Interested in policy development, she received an NMRC Award, enrolled in the John Hopkins Bloomberg School of Public Health, and graduated in December 2009 with a Master of Public Health and an additional Diploma in Health Policy and Financial Management. She returned to work at the National Cancer Centre Singapore (NCCS), as a Senior Consultant and was appointed the Director of the NCCS Centre for Peritoneal and Pelvic Disease. The centre now has the largest experience with the surgical management of peritoneal-based malignancies in Asia. She has extensive experience in the management of colorectal, gastric, oesophageal and pelvic cancers, along with that of sarcomas and melanomas.
She has been a strong advocate for improving cancer care in Singapore, and is a member of the Singapore Society of Oncology, sits on the Singapore Cancer Network Sarcoma Guideline Committee and is a member of the Ministry of Health Technology Advisory Committee. At NCCS, she co-chairs the Paediatrics/Sarcoma/ Melanoma workgroup and member of the Gastrointestinal Tract workgroup for NCCS Cancer Service Line. She is the vice-chair for Faculty Affairs and Professional Development in ACP Surgery. She is also the chairperson for the new NCCS Building Committee and Director of Strategic Initiatives of ACP Oncology. Adj Prof Teo holds many research leadership positions and is the PI of more than 43 IRBs, authored more than 120 peer-reviewed publications, and 6 book chapters.
Her mission as a surgical oncologist is to improve cancer care in Singapore and the region, through increased patient awareness of the disease, and its management, contributing to the setting of guidelines and pushing the frontiers for cancer management in her areas of expertise and education of the next generation of surgical residents, clinical fellows and medical students.


  • MPH (Johns Hopkins) 
  • FRCS(Edin)
  • FAMS (Singapore) 
  • MMed (Surgery) 
  • MBBS (Singapore)


  • Surgical Oncology (University of Toronto)
  • Colorectal Surgery (University of Toronto)

Professional Appointments and Committee Memberships

  • Member, Singapore Medical Association
  • Member, General Medical Council (UK)
  • Fellow of Academy of Medicine, Singapore
  • Fellow of Royal College of Surgeons, Edinburgh
  • Member, The College of Physicians and Surgeons of Ontario
  • Member, Canadian Society of Surgical Oncology
  • Member, The Society of Surgical Oncology, Inc
  • Adjunct Assistant Professor, Yong Loo Lin School of Medicine (Jan 2017 to Jul 2018)
  • Adjunct Professor, Duke-NUS Medical School (Aug 2018 to Jul 2021)


  • Outstanding Faculty Award – Residency in SingHealth Excels (RiSE), 2018
  • AM-ETHOS Duke-NUS Medical Student Fellowship (Duke-NUS MSF) Award, 2017
  • NCC Research Fund July 2016 Grant Call
  • Special Recognition Award for Role Model to Medicine Graduating Class of 2016 – National University of Singapore
  • DukeNUS Medical School  - Outstanding Faculty for Surgery, 2016
  • SingHealth Excellence Award 2015 – Distinguished Young Leader Award
  • DukeNUS Medical School - Outstanding Faculty for Surgery, 2015
  • Certificate of Commendation for being a Role Model to the Class of 2014 – Yong Loo Lin School of Medicine
  • Yong Loo Lin School of Medicine Awards and Appreciation Nite 2013: Outstanding Tutor Award
  • NMRC Clinician Scientist: Individual Research Grant (CS-IRG), 2013
  • Outstanding Faculty Award – voted by your residents at the RISE award 2013
  • Terry Fox Research Grant – Molecular Signature of Peritoneal Metastasis, 2012
  • Yong Loo Lin School of Medicine: Best Tutor Awards, 2012
  • Service With A Heart Award, Singapore General Hospital, 2012
  • Surgical Star – Inspiring Teacher Award (Division of Surgery, SGH), 2011
  • NMRC Research Training Fellowship – MPH (John Hopkins Bloomberg School of Public Health), 2008

Publications and Research Trials

Top 10 articles

  1. First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum.
  2. Healthcare Worker Seroconversion in SARS outbreak
  3. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
  4. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
  5. Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
  6. 201 Consecutive Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Procedures in a Single Asian Tertiary Centre
  7. Acute Kidney Injury In Ovarian Cancer Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
  8. Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing CRS and HIPEC?
  9. Exploring the trend in referrals for consideration of CRS and HIPEC to understand the attitudes of clinicians in the development of a national cancer centre program in Peritoneal disease
  10. Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Research Trials